FALDAPREVIR SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H48BrN6O9S.Na
Molecular Weight	891.803
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].COC1=CC=C2C(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](NC(=O)OC4CCCC4)C(C)(C)C)C(=O)N[C@@]5(C[C@H]5C=C)C([O-])=O)=CC(=NC2=C1Br)C6=CSC(NC(=O)C(C)C)=N6

InChI

InChIKey=JYIOGGWFNHGWMN-CWNXUBRBSA-M

InChI=1S/C40H49BrN6O9S.Na/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41;/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48);/q;+1/p-1/t21-,23-,27+,32-,40-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C40H48BrN6O9S
Molecular Weight	868.813
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25749475 | https://www.ncbi.nlm.nih.gov/pubmed/25633983 | https://www.ncbi.nlm.nih.gov/pubmed/24373080

Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor developed by Boehringer-Ingelheim for the treatment of hepatitis C. Faldaprevir in combination with pegylated interferon and ribavirin, or interferon-free treatment with faldaprevir in combination with deleobuvir plus ribavirin provides high sustained virological response rates for HCV genotype 1 infection. The most common adverse events were gastrointestinal disorders, rash, and photosensitivity. The interferon-free combination of faldaprevir and deleobuvir with ribavirin was effective for HCV genotype 1 infection, although further improvements will still be needed. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.

Approval Year

PubMed

Title	Date	PubMed
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.	2013-08-01	23773863

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:27:31 GMT 2025` Edited by `admin` on `Mon Mar 31 18:27:31 GMT 2025`
Record UNII	1494Q15E7Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BI 201335 NA

Preferred Name

English

FALDAPREVIR SODIUM

Official Name

English

BI-201335 SODIUM SALT

Code

English

BI-201335-NA

Code

English

FALDAPREVIR, SODIUM SALT

Common Name

English

Faldaprevir sodium [WHO-DD]

Common Name

English

BI-201335NA

Code

English

BI-201335 NA SALT

Code

English

FALDAPREVIR SODIUM [JAN]

Common Name

English

FALDAPREVIR SODIUM [USAN]

Common Name

English

BI-201335 NA

Code

English

Code System Code Type Description

USAN

AB-20